He wasn’t “stressed.” His hormones were running a sophisticated civil war, and nobody had bothered to look at the battlefield properly.
The problem wasn’t that his doctors were incompetent. The problem was they were using a butter knife to do surgery. Standard blood panels check total testosterone, maybe free testosterone, maybe TSH. That’s roughly equivalent to checking whether a car has gasoline and declaring the engine healthy. Hormones run in cascades, feedback loops, and conversion pathways that require specific testing to actually understand.
The DUTCH test — Dried Urine Test for Comprehensive Hormones — exists precisely because clinicians and researchers recognized that serum hormone levels were telling an incomplete story.
When Marcus finally got a DUTCH Complete test, the results told a story his serum panels had been obscuring for three years. His testosterone was converting excessively to estradiol via aromatase. His cortisol metabolites showed a pattern consistent with HPA axis dysregulation — not total adrenal failure, but a specific type of functional blunting that caused evening cortisol to spike when it should have been falling. His melatonin was nearly undetectable.
And his estrogen metabolism was proceeding almost entirely through the 16-OH pathway rather than the protective 2-OH pathway. None of this showed up in standard bloodwork. All of it was fixable. That’s what the DUTCH test does.
What the DUTCH Test Actually Measures (And Why It Matters)
The DUTCH test was developed by Mark Newman, MS, at Precision Analytical Laboratory in 2012. The insight driving its development was simple: urine hormone metabolites give a far more comprehensive picture of hormone production, metabolism, and clearance than serum levels alone. Check serum hormone levels and what’s being seen is a snapshot — what’s circulating at a single moment, nothing more.
Urine testing over a full 24-hour period — or the DUTCH method specifically, which uses dried urine spots collected at four to five time points — captures the metabolic end products of hormone activity. The full story, not a frame of it.
The test measures several distinct hormone categories. For cortisol and the HPA axis: free cortisol at multiple time points throughout the day (waking, morning, afternoon, night), total cortisol metabolites (THF + allo-THF + THE), and DHEA-S. That combination shows both the diurnal rhythm of cortisol secretion and the total cortisol burden the body is producing.
The ratio of metabolized to free cortisol reveals cortisol clearance efficiency — how quickly the liver processes cortisol, which determines how long each cortisol pulse lingers in the system.
For sex hormones, the DUTCH measures estradiol, estrone, estriol (the three main estrogens), progesterone metabolites (pregnanediol), testosterone, and DHEA. More importantly, it measures their downstream metabolic products: 2-OH estrone, 4-OH estrone, and 16-OH estrone for estrogen; androsterone and etiocholanolone for androgens. These metabolites reveal where hormones are going after they’re produced — a question serum panels don’t even ask.
The test also quantifies the methylation capacity of estrogen metabolism through the 2-methoxy estrone marker, which shows whether the body is efficiently converting the potentially problematic 2-OH estrone into its inert methylated form. That requires adequate methylation cofactors — folate, B12, B6, magnesium — meaning the DUTCH test can double, almost by accident, as a functional methylation screen.
Reading the Cortisol Map: The Four-Point CAR and Diurnal Rhythm
The cortisol section of the DUTCH report is where many practitioners find the most actionable data, particularly for patients presenting with fatigue, sleep disruption, anxiety, or immune dysregulation. Understanding it requires grasping the Cortisol Awakening Response (CAR) and the diurnal cortisol curve.
Under normal physiology, cortisol follows a precise daily rhythm driven by the suprachiasmatic nucleus and the HPA axis. It surges within 30 to 45 minutes of waking — the CAR — peaks in the morning, then gradually declines throughout the day to reach its nadir around midnight. This rhythm does several jobs at once: mobilizes energy for the day, modulates immune activity, regulates blood sugar, and allows melatonin to rise as cortisol falls in the evening.
When this rhythm breaks down, the downstream consequences pile up: poor sleep onset, disrupted glucose metabolism, immune dysregulation, cognitive impairment, mood instability.
The DUTCH test captures waking, morning (30-60 minutes post-waking), afternoon, and evening free cortisol. A healthy pattern shows a pronounced waking spike, a sustained morning peak, a meaningful afternoon decline, and low evening values. Practitioners commonly see several pathological patterns. In the “cortisol steal” pattern — a controversial but clinically observed phenomenon sometimes called “pregnenolone steal” — precursor hormones get shunted toward cortisol production at the expense of sex hormones, producing low testosterone, low estrogen, and high cortisol metabolites simultaneously.
The flattened diurnal pattern — where morning cortisol is already low and evening cortisol is only marginally lower — represents HPA axis blunting. Distinct from the classic “adrenal fatigue” narrative of simply depleted cortisol. Research by Robert Sapolsky at Stanford and Dirk Hellhammer at the University of Trier has documented this blunting pattern in chronic psychological stress, PTSD, burnout, and prolonged inflammation.
The mechanism involves downregulation of CRH receptors in the anterior pituitary and glucocorticoid receptor insensitivity — not adrenal gland failure per se.
High evening cortisol is perhaps the most common finding in patients with insomnia and anxiety. When cortisol stays elevated at 9 or 10 p.m., it directly suppresses melatonin release and maintains physiological arousal that makes sleep onset difficult. The DUTCH test simultaneously measures melatonin (as 6-OHMS, its primary urine metabolite), which lets clinicians directly document the cortisol-melatonin antagonism they’ve long suspected but rarely confirmed with actual lab data.
Estrogen Metabolism: The Three Pathways That Determine Your Cancer Risk
If the cortisol section is the most immediately actionable part of the DUTCH test, the estrogen metabolite section may be the most consequential for long-term health outcomes. The liver metabolizes estrogens through three competing pathways, and the ratio of metabolites produced determines both symptom burden and long-term breast and prostate cancer risk.
The 2-hydroxylation pathway converts estradiol and estrone into 2-hydroxyestrone (2-OHE1), sometimes called the “good” or protective estrogen. 2-OHE1 has weak estrogenic activity and, crucially, acts as an antioxidant — multiple epidemiological studies, including the Bethesda Estrogen Study and the Nurses’ Health Study, found inverse associations between urinary 2-OHE1 levels and breast cancer incidence.
Critically, 2-OHE1 can be further methylated into 2-methoxy estrone (2-ME1) by COMT (catechol-O-methyltransferase), which has demonstrated anti-angiogenic and pro-apoptotic properties in cancer cell lines.
The 16-hydroxylation pathway produces 16-alpha-hydroxyestrone (16alpha-OHE1), a potent estrogen agonist that can form semi-permanent covalent bonds with estrogen receptors. Unlike the reversible binding of estradiol, that semi-permanent binding delivers a prolonged estrogenic stimulus. Epidemiological data, while not perfectly consistent, generally associates elevated 16alpha-OHE1 with increased breast cancer risk, particularly in premenopausal women.
High 16alpha-OHE1 also shows up alongside estrogen-dominant symptoms: heavy periods, fibrocystic breasts, mood swings, fat deposition around hips and thighs, exaggerated PMS.
The 4-hydroxylation pathway is the most concerning of the three. 4-hydroxyestrone (4-OHE1) is a catechol estrogen that can be oxidized to a semiquinone and then a quinone — reactive electrophiles that form DNA adducts. In the presence of inadequate COMT activity (genetically reduced, or functionally impaired by magnesium deficiency or chronic stress), 4-OHE1 accumulates and participates in DNA damage cycles. Animal studies have confirmed that 4-OHE1 is directly carcinogenic.
Human data is messier, but elevated 4-OHE1 with low methylation efficiency represents a concerning metabolic pattern that warrants intervention regardless.
The DUTCH report expresses these as ratios: the 2:16 ratio (protective vs. proliferative estrogens) and the methylation ratio (2-ME1:2-OHE1, reflecting COMT efficiency). A 2:16 ratio above 2.0 is generally considered protective. The methylation ratio should ideally sit above 0.3, meaning at least 30% of 2-OHE1 is being methylated to its inert form. When that ratio runs low, interventions like diindolylmethane (DIM), indole-3-carbinol (I3C), cruciferous vegetables, folate, magnesium, and COMT-supporting nutrients become clinically relevant.
Testosterone Metabolism and the Androgen Pathway
Elevated 5-alpha reductase activity produces excess DHT, driving scalp hair loss, benign prostatic hyperplasia, prostate enlargement, and acne. The DUTCH test measures the 5alpha:5beta metabolite ratio (androsterone:etiocholanolone), a proxy for 5-alpha reductase activity. Men with high-DHT symptoms but normal testosterone benefit from this information directly — it justifies interventions targeting 5-alpha reductase (saw palmetto, dutasteride, finasteride) rather than testosterone replacement therapy.
Elevated aromatase activity — the enzyme converting testosterone to estradiol — is an increasingly common finding in men, particularly those carrying excess adipose tissue, metabolic dysfunction, or chronic inflammation. Fat tissue is the primary site of peripheral aromatization, meaning obesity directly drives estrogen elevation and testosterone suppression in men. The DUTCH test documents this by showing normal or even elevated testosterone metabolites alongside elevated estrogen metabolites — active conversion, caught in the act.
Serum testosterone alone might look borderline low while the real problem is excessive aromatization.
For women, the androgen section reveals conditions like polycystic ovarian syndrome (PCOS), where excess androgens show up as elevated testosterone metabolites, often alongside elevated 5-alpha reductase activity (explaining hirsutism and acne). Functional medicine practitioners have documented PCOS presentations where the DUTCH test clarifies the specific androgen pattern — some women have primarily elevated DHT from high 5-alpha reductase activity with normal testosterone, others show genuine testosterone overproduction from the ovaries. Different patterns, different interventions.
DHEA, Pregnenolone, and the Upstream Hormone Picture
DHEA (dehydroepiandrosterone) is produced primarily in the adrenal cortex and is the most abundant circulating steroid hormone in young adults, with levels declining roughly 80% between age 25 and 80. The DUTCH test measures DHEA-S (the sulfated, stable storage form) and DHEA metabolites, revealing not just DHEA levels but DHEA production patterns relative to cortisol output.
The DHEA:cortisol ratio is a key metric. Under chronic stress, the ratio shifts toward cortisol dominance — more cortisol metabolites, lower DHEA metabolites. This ratio has been studied as a biomarker of biological aging and physiological resilience. Research published in Psychoneuroendocrinology has associated low DHEA:cortisol ratios with accelerated cognitive decline, reduced immune function, higher cardiovascular risk, and worse survival outcomes in critically ill patients.
The adrenal glands use the same enzymatic machinery for both DHEA and cortisol synthesis; chronic ACTH stimulation from stress can shift output toward cortisol at DHEA’s expense.
Pregnenolone is the mother of all steroid hormones — derived directly from cholesterol, it’s the precursor to progesterone, DHEA, cortisol, testosterone, estrogen, and aldosterone. The DUTCH test doesn’t directly measure pregnenolone (it’s not efficiently excreted in urine), but its levels can be inferred from the pattern of downstream metabolites. Very low progesterone metabolites alongside very low DHEA metabolites and normal or elevated cortisol often signals pregnenolone insufficiency, sometimes warranting pregnenolone supplementation as an upstream intervention.
Progesterone and Luteal Phase Deficiency in Women
Progesterone is perhaps the most underappreciated hormone in women’s health, and the DUTCH test’s measurement of pregnanediol (the primary urine metabolite of progesterone) provides important information that serum progesterone testing often misses due to its pulsatile secretion. Progesterone is secreted in pulses by the corpus luteum following ovulation, meaning a single serum draw can catch a pulse peak or a trough and badly misrepresent average luteal output.
Luteal phase deficiency — inadequate progesterone production in the second half of the menstrual cycle — is significantly underdiagnosed. Symptoms: premenstrual syndrome, anxiety, insomnia, heavy or irregular periods, spotting before menstruation, difficulty conceiving or maintaining early pregnancy. Because progesterone is a potent GABA-A receptor positive allosteric modulator (via its neurosteroid metabolite allopregnanolone), low progesterone produces anxiety and insomnia symptoms that are often treated with psychiatric medications rather than addressed at their actual hormonal source.
The DUTCH test, when collected on day 19-21 of a 28-day cycle (the luteal phase peak), captures pregnanediol in a way that reflects integrated production over the preceding day rather than a single pulsatile measurement. Values below 1.5 micrograms per milligram creatinine are generally considered consistent with luteal phase deficiency.
Importantly, the test can also reveal whether supplemented progesterone (oral micronized progesterone, topical creams) is being adequately absorbed and metabolized, by comparing pregnanediol excretion to the expected amount from a given dose.
Organic Acids and Nutritional Markers: What DUTCH Plus Adds
The 8-OHdG marker is particularly valuable. It’s a DNA oxidation product — specifically, guanine oxidized by reactive oxygen species. Elevated 8-OHdG in urine signals systemic oxidative DNA damage, which connects directly to the cancer risk discussion in the estrogen metabolism section above. When a patient shows unfavorable estrogen metabolite ratios (high 4-OHE1, low methylation) alongside elevated 8-OHdG, the case for aggressive antioxidant and methylation support gets considerably stronger.
Neurotransmitter metabolites add another layer of clinical context. Vanilmandelic acid (VMA) and homovanillic acid (HVA) are breakdown products of epinephrine/norepinephrine and dopamine respectively. Elevated VMA and HVA point to high sympathetic nervous system output and dopamine turnover — consistent with chronic psychological stress, stimulant use, or catecholamine-producing tumors. Low HVA relative to expected values can indicate dopamine depletion, which shows up clinically as motivation deficits, executive dysfunction, and anhedonia.
The Melatonin Section: Chronobiology and Sleep Architecture
Melatonin is measured on the DUTCH test as 6-hydroxymelatonin sulfate (6-OHMS), the primary urinary metabolite. Clinically significant because it reflects total melatonin production over the night rather than a single measurement at one point in time. The reference range for overnight 6-OHMS in adults runs roughly 14-68 micrograms per milligram creatinine, with levels declining significantly with age — 70-year-olds typically produce 70-80% less melatonin than 20-year-olds.
Low melatonin on the DUTCH test contextualizes insomnia complaints in a way clinical history alone can’t. When a patient reports difficulty falling asleep and the DUTCH shows both high evening cortisol and low 6-OHMS, the physiological mechanism is confirmed: cortisol is directly suppressing melatonin synthesis via inhibition of the AANAT enzyme (arylalkylamine N-acetyltransferase), the rate-limiting step in melatonin production.
Which turns evening blue light exposure, high-intensity exercise in the evening, and psychological stress within two hours of bedtime into documented physiological problems rather than generic wellness suggestions.
Notably, some practitioners have observed that standard melatonin supplementation (0.5-5 mg at bedtime) doesn’t reliably raise 6-OHMS levels on subsequent DUTCH testing — suggesting exogenous melatonin may suppress endogenous production through negative feedback. Still debated in the literature, but consistent with the general principle that hormone supplementation can downregulate endogenous synthesis. Worth discussing with anyone leaning heavily on melatonin supplements.
Timing the DUTCH Test: Cycle-Phase Protocols for Women
For premenopausal women, timing is critical to accurate interpretation. The sex hormone section — particularly progesterone metabolites and the estrogen:progesterone ratio — changes dramatically across the menstrual cycle. Testing in the follicular phase (days 1-13 of a 28-day cycle) will show low progesterone and rising estrogen, which is completely normal. Testing in the luteal phase (days 19-22 of a 28-day cycle) captures peak progesterone and the estrogen:progesterone balance that determines symptoms like PMS and anxiety.
Recommended timing is days 19-22 of a typical 28-day cycle, or 7 days before the anticipated period if cycles are irregular. For women with irregular cycles or anovulation (common in PCOS, perimenopause, or high-stress states), interpreting progesterone metabolites requires knowing whether ovulation occurred at all — absent ovulation means absent corpus luteum means near-zero luteal progesterone is expected and doesn’t indicate luteal phase deficiency per se.
For postmenopausal women and men, cycle timing is irrelevant, and the test can be collected any day. For women on hormonal contraceptives, the DUTCH test gives limited information about endogenous sex hormone production, because synthetic progestins and ethinyl estradiol suppress the HPG axis. Some practitioners still run DUTCH testing on women taking hormonal contraceptives specifically to assess cortisol rhythm and melatonin, acknowledging that the sex hormone section mostly reflects the synthetic hormones rather than endogenous production.
DUTCH Testing on Hormone Replacement Therapy
Research published in the journal Steroids by Fuhrman and colleagues at Precision Analytical found that women using topical progesterone showed dramatically higher pregnanediol excretion on DUTCH testing compared to serum progesterone levels — confirming the DUTCH test as the superior monitoring tool for transdermal progesterone.
For testosterone replacement, similar dynamics apply. Men using testosterone cypionate injections or topical gels need DUTCH testing not just to confirm adequate testosterone delivery but to monitor the downstream conversion picture (aromatization to estradiol, 5-alpha-reductase activity to DHT).
The clinical implication matters: a man on testosterone replacement therapy who complains of persistent erectile dysfunction, gynecomastia, or water retention despite “normal” serum testosterone might show high estradiol metabolites and high aromatase activity on DUTCH testing — a pattern that warrants aromatase inhibitor therapy (anastrozole, DIM, or zinc supplementation) rather than continued testosterone dose increases.
Collection Protocol and Common Mistakes
The DUTCH test uses dried urine collected at four or five specific time points. The standard DUTCH Complete collection involves: waking specimen (before eating or drinking), 2 hours post-waking specimen, afternoon specimen (2-3 p.m.), and bedtime specimen. The DUTCH Plus adds a second waking specimen to better capture the Cortisol Awakening Response spike at 30 minutes post-waking. Collection involves urinating on filter paper strips, air-dried for a minimum of 24 hours before mailing to the lab.
Common collection errors that compromise results: inadequate drying of the filter paper (mold growth degrades hormones), excessive fluid intake diluting the sample (aim for normal hydration, not heroic water consumption), vigorous exercise on collection days (transiently elevates cortisol and testosterone metabolites), certain supplements interfering with results (high-dose B vitamins can interfere with some assays; biotin supplementation above 5 mg/day can interfere with immunoassay-based measurements), inconsistent timing of specimens.
Patients should ideally stop biotin supplementation 72 hours before collection, avoid intense exercise on collection days, and maintain their normal sleep schedule rather than attempting collection during travel or unusual circumstances. Women should confirm their cycle day before beginning collection.
For patients on exogenous hormones, timing of the last dose relative to collection matters — practitioners typically advise collecting 24-48 hours after the last progesterone or estrogen dose for a more accurate peak-level assessment, though protocols vary by clinical goal.
Interpreting the Report: A Systematic Framework
The DUTCH report is visually dense, and many practitioners — even experienced clinicians — feel initially overwhelmed by its scope. A systematic interpretation framework helps. Start with the overview graph, which shows all major hormone metabolites on a spectrum from low to high relative to the reference population.
That bird’s-eye view quickly identifies whether the pattern is globally low (consistent with HPA axis suppression or low precursor availability), globally high (consistent with high production or slow clearance), or mixed (elevated in some categories, depressed in others).
Next, examine the cortisol diurnal curve specifically. Note the waking value (is there a meaningful CAR?), the peak timing and magnitude, and particularly the evening value relative to the waking value. Evening cortisol should sit below 30% of waking cortisol in a healthy rhythm. Then compare free cortisol to metabolized cortisol: if free cortisol is low but metabolized cortisol is normal or high, cortisol clearance is fast (high cortisol turnover, often seen in thyroid dysfunction or obesity).
If free cortisol is normal but metabolized cortisol is very high, production is high even though free levels look managed.
Move to the estrogen section and note the 2:16 ratio and the methylation ratio. Then examine the androgen section against the patient’s clinical presentation. Finally, review DHEA relative to cortisol, and melatonin in the context of the evening cortisol finding. Piece together a narrative: What’s the HPA axis doing? What are sex hormones doing? How are they being metabolized? Where are the intervention points?
Clinical Conditions Where DUTCH Testing Changes Management
The DUTCH test has its highest clinical yield in specific presentations. Perimenopause and menopause management benefit enormously because the test quantifies not just hormone levels but the metabolic patterns that determine HRT safety and dosing.
A postmenopausal woman with osteoporosis considering estrogen therapy who shows a 2:16 ratio of 0.8 and a methylation ratio of 0.15 has a very different risk profile than one with a ratio of 3.2 and 0.45 — and that difference should inform dosing strategy and adjunctive nutrient support.
Male hypogonadism evaluation benefits from DUTCH testing when total testosterone is borderline (300-400 ng/dL range) and serum panels are inconclusive. The combination of testosterone metabolite levels, estrogen metabolite levels, and the aromatization pattern can differentiate primary testicular hypogonadism from secondary (HPG axis suppression) from normal testosterone with excessive aromatization — three scenarios that require completely different treatments.
Chronic fatigue, burnout, and fibromyalgia are conditions where HPA axis assessment via DUTCH testing consistently turns up actionable findings. Multiple studies have documented HPA axis dysregulation in fibromyalgia, with blunted cortisol awakening responses and altered diurnal curves appearing in controlled comparisons to healthy subjects. The DUTCH test operationalizes these research findings into clinical practice. Premenstrual dysphoric disorder (PMDD), endometriosis, uterine fibroids, and polycystic ovarian syndrome all have hormone metabolite patterns that the DUTCH illuminates and that guide targeted intervention.
Limitations and What the DUTCH Test Cannot Do
Intellectual honesty demands acknowledging the limitations. The DUTCH test doesn’t replace serum hormone testing — the two provide complementary information. Acute hormone level assessment (estradiol surge at LH peak during fertility monitoring, for instance) still requires serum testing. The DUTCH test also can’t measure peptide hormones like LH, FSH, prolactin, insulin, leptin, or thyroid hormones, all critical for a complete hormonal picture.
A comprehensive evaluation typically combines DUTCH testing with serum LH, FSH, TSH, free T3, free T4, fasting insulin, and fasting glucose at minimum.
The reference ranges Precision Analytical uses are population-based percentile distributions, not clinically validated threshold values. A result in the “normal” range doesn’t guarantee normal function, and a result outside the reference range doesn’t automatically mean pathology. Clinical interpretation has to integrate symptoms, clinical history, other lab findings, and practitioner experience. The test is also expensive — typically $400-500 USD out of pocket — and not covered by most insurance plans, which limits access and raises real equity concerns.
Finally, the DUTCH test hasn’t been extensively validated against clinical outcomes. It’s physiologically rational and captures real metabolic information, but there’s limited randomized controlled trial data showing that treating based on DUTCH results produces better health outcomes than treating based on symptoms and standard testing alone. That doesn’t make the test invalid. It makes it a sophisticated clinical tool that requires sophisticated clinical interpretation — not a standalone diagnostic oracle.
What People Ask About DUTCH Test Actually
Q: How is the DUTCH test different from a 24-hour urine collection?
Traditional 24-hour urine hormone testing collects all urine over a full day, giving a good measurement of total hormone metabolites but completely losing the diurnal rhythm information. The DUTCH test captures hormones at specific time points throughout the day, allowing assessment of the cortisol awakening response, the afternoon decline, and the evening nadir — patterns a 24-hour average simply can’t show.
The dried urine format also makes collection far more practical than hauling around a large urine jug for 24 hours.
Q: Should I get a DUTCH test or a serum hormone panel?
Ideally both, since they serve complementary purposes. A serum panel measures acute circulating levels at the moment of the draw and includes peptide hormones (LH, FSH, prolactin) the DUTCH doesn’t capture. The DUTCH measures integrated hormone metabolites throughout the day, diurnal cortisol rhythm, estrogen metabolism pathways, and melatonin.
If limited to one test, and the primary concerns are chronic fatigue, sleep disruption, hormonal symptoms, or HRT monitoring, the DUTCH provides more actionable information. If the concern is fertility, thyroid function, or suspected LH/FSH abnormalities, serum testing is essential.
Q: Can the DUTCH test diagnose adrenal fatigue?
“Adrenal fatigue” as a discrete diagnostic entity doesn’t have strong scientific support — the adrenal glands rarely actually fail in otherwise healthy people. What the DUTCH test can diagnose is HPA axis dysregulation: specific patterns of blunted cortisol awakening response, altered diurnal rhythm, or elevated cortisol metabolites with low free cortisol (suggesting fast clearance).
These are real, measurable, treatable physiological phenomena that explain the fatigue symptoms often blamed on “adrenal fatigue.” The DUTCH test makes these patterns visible and quantifiable rather than presumed.
Q: How often should I repeat the DUTCH test after making changes?
Most practitioners recommend retesting 3-6 months after implementing interventions. Hormone patterns take time to shift: cortisol rhythm improvements from sleep optimization and stress management typically emerge over 8-12 weeks; nutritional interventions supporting estrogen methylation (DIM, folate, B12, magnesium) generally show measurable effects in 3-4 months; testosterone replacement therapy stabilization takes 6-12 weeks to reach steady state.
Testing too soon (under 6-8 weeks) captures transitional patterns rather than stable new baselines.
Q: Does the DUTCH test require a doctor’s order?
In the United States, DUTCH testing is available through licensed practitioners (MDs, NDs, DCs, DOs, PAs, NPs, and in some states, certified health coaches and nutritionists). Several direct-to-consumer lab services also offer DUTCH testing without a practitioner order, though Precision Analytical themselves recommend provider-supervised testing for proper interpretation.
Given the complexity of the report and the clinical decisions it informs, working with a practitioner experienced in functional or integrative medicine provides substantially more value than self-interpreting the results.
Q: What should I do if my DUTCH test shows an unfavorable estrogen metabolism pattern?
An unfavorable estrogen metabolism pattern — low 2:16 ratio, low methylation ratio, elevated 4-OHE1 — warrants a multi-pronged response. First, increase consumption of cruciferous vegetables (broccoli, Brussels sprouts, cabbage, cauliflower), which contain glucobrassicin, a precursor to indole-3-carbinol and DIM that directly upregulates 2-hydroxylation. Second, ensure adequate methylation cofactors: methylfolate, methylcobalamin B12, magnesium glycinate, and B6 in its pyridoxal-5-phosphate form.
Third, consider DIM supplementation, taken with food, as a more concentrated cruciferous-derived compound. Fourth, reduce alcohol, which potently inhibits CYP1A2 (the enzyme driving 2-hydroxylation) and raises estrogen levels through multiple mechanisms. Fifth, optimize body composition — adipose tissue is the primary site of aromatase activity and 16-hydroxylation. Retest in 3-4 months to document the response.
The Role of Liver Function in Hormone Metabolism
One aspect of the DUTCH test that practitioners frequently underemphasize is what it reveals about liver function. The liver is the primary site of steroid hormone metabolism and conjugation — it clears spent hormones from circulation, converts them into water-soluble forms for excretion, and drives the specific hydroxylation pathways that determine estrogen metabolite ratios.
When liver function is suboptimal, even below the threshold for abnormal liver enzymes on a standard panel, hormone metabolism can be profoundly affected.
Phase I liver detoxification (cytochrome P450 enzymes, particularly CYP1A1, CYP1A2, and CYP3A4) drives estrogen hydroxylation. Phase II liver detoxification (glucuronidation, sulfation, methylation) conjugates hormone metabolites for excretion. Disruptions at either phase alter hormone clearance and metabolite ratios. Alcohol consumption, for instance, induces CYP3A4 (increasing 16-hydroxylation) while depleting methylation cofactors (decreasing 2-methoxy estrone formation) — a double hit on estrogen metabolism the DUTCH test can document.
Non-alcoholic fatty liver disease (NAFLD), which affects roughly 25% of Western adults, is associated with impaired sex hormone binding globulin (SHBG) production and altered steroid hormone clearance. Patients with NAFLD frequently show elevated estrogen metabolites on DUTCH testing not because they’re producing more estrogen but because their livers are clearing it more slowly. That distinction — production excess versus clearance deficit — carries different therapeutic implications.
Improving liver function through carbohydrate restriction, weight loss, and liver-supportive compounds (NAC, milk thistle, taurine) addresses the clearance deficit, while estrogen receptor modulators address production excess.
The glucuronidation pathway deserves specific mention. After Phase I hydroxylation, estrogen metabolites are conjugated with glucuronic acid by UGT enzymes in the liver, rendering them water-soluble and ready for biliary excretion. In the gut, beta-glucuronidase enzymes produced by certain gut bacteria can cleave this glucuronide bond, liberating the estrogen metabolite for reabsorption — a process sometimes called “estrogen recycling,” or entero-hepatic circulation of estrogens.
High beta-glucuronidase activity (driven by high-meat, low-fiber diets and dysbiotic gut microbiomes) increases estrogen reabsorption and can elevate total estrogen burden independent of production. Calcium-D-glucarate, a compound found in citrus fruits and apples, inhibits beta-glucuronidase and can complement the DUTCH findings in patients with elevated estrogen metabolites.
Connecting DUTCH Results to Genetic Testing
The DUTCH test and genetic testing (SNP analysis via 23andMe, AncestryDNA, or clinical genetics panels) work powerfully in combination, because the DUTCH measures functional enzyme activity while genetics explains why that activity is elevated or reduced. The most clinically relevant gene-metabolite connections involve COMT, CYP1B1, MTHFR, and UGT enzymes.
COMT (catechol-O-methyltransferase) is the enzyme responsible for methylating 2-OHE1 into 2-methoxy estrone. The Val158Met polymorphism (rs4680) is the most studied COMT variant. Individuals with two copies of the Met allele (sometimes called “slow COMT” or COMT++) have roughly 40% lower COMT enzyme activity than Val/Val homozygotes. On the DUTCH test, slow COMT shows up as a low methylation ratio (2-ME1:2-OHE1 below 0.2) despite normal or high 2-OHE1 production — the bottleneck is in the methylation step, not the hydroxylation step.
These individuals have a physiologically higher need for methylation cofactors and carry greater theoretical risk from the 2-OHE1 accumulation that occurs once methylation capacity saturates.
CYP1B1 is the enzyme that drives 4-hydroxylation of estrogens. CYP1B1 polymorphisms (particularly rs1056836) are associated with altered 4-OHE1 production. Women carrying certain CYP1B1 variants have shown, in case-control studies, modestly elevated breast cancer risk — particularly in combination with slow COMT variants, consistent with the mechanistic model where high 4-OHE1 production meets impaired catechol estrogen methylation. The DUTCH test makes this theoretical risk visible in real metabolic data rather than pure genetic probability.
MTHFR (methylenetetrahydrofolate reductase) mutations (C677T and A1298C) reduce the enzyme’s ability to convert folate to its active methyl-folate form, impairing the entire one-carbon methylation cycle. Since COMT requires S-adenosylmethionine (SAM) as its methyl donor — and SAM synthesis requires adequate methylation cycle function — MTHFR mutations can indirectly impair estrogen methylation. Patients with MTHFR C677T homozygosity and low DUTCH methylation ratios benefit most aggressively from methylfolate supplementation, bypassing the enzymatic bottleneck entirely.
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map